Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies

Cancer Science

Volumn 100, Issue 6, 2009, Pages 990-995

  Goyama, Susumu ^a,b   Kurokawa, Mineo ^a  

^a Hematology and Oncology   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ECOTROPIC VIRAL INTEGRATION SITE 1; ONCOPROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GATA 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EVI1 PROTEIN, HUMAN; MESSENGER RNA; TRANSCRIPTION FACTOR;

CELL DIFFERENTIATION; CHROMOSOMAL LOCALIZATION; CHROMOSOME REARRANGEMENT; CLINICAL FEATURE; ECOTROPIC VIRUS; ENZYME ACTIVITY; GENE ACTIVITY; GENE FUNCTION; GENE INSERTION; GENE LOCUS; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; INFECTION SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS CARCINOGENESIS; ALTERNATIVE RNA SPLICING; ANIMAL; BLOOD DISEASE; CHROMOSOME 3; CHROMOSOME BANDING PATTERN; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENETICS; HEMATOPOIESIS; LEUKEMIA; MOUSE; PHYSIOLOGY; PROTO ONCOGENE; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

ALTERNATIVE SPLICING; ANIMALS; CELL DIFFERENTIATION; CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 3; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENETIC VARIATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HUMANS; LEUKEMIA; MICE; PROGNOSIS; PROTO-ONCOGENES; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VIRUS INTEGRATION;

EID: 67649882141     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01152.x     Document Type: Review

References (57)

1. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988, 54:831-40.
2. Mucenski ML, Taylor BA, Ihle JN. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 1988, 8:301-8.
3. Morishita K, Parganas E, Bartholomew C. The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t(3;5)(q25;q34) translocations. Oncogene Res 1990, 5:221-31.
4. Wieser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 2007, 396:346-57.
5. Morishita K, Parganas E, Douglass EC, Ihle JN. Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene 1990, 5:963-71.
6. Matsugi T, Morishita K, Ihle JN. Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene. Mol Cell Biol 1990, 10:1259-64.
7. Bordereaux D, Fichelson S, Tambourin P, Gisselbrecht S. Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ by the number of zinc finger motifs. Oncogene 1990, 5:925-7.
8. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 1996, 93:1642-7.
9. Mitani K, Ogawa S, Tanaka T. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994, 13:504-10.
10. Nitta E, Izutsu K, Yamaguchi Y. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene 2005, 24:6165-73.
11. Perkins AS, Fishel R, Jenkins NA, Copeland NG. Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol 1991, 11:2665-74.
12. Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 1993, 13:4291-300.
13. Morishita K, Suzukawa K, Taki T, Ihle JN, Yokota J. EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC. Oncogene 1995, 10:1961-7.
14. Yuasa H, Oike Y, Iwama A. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005, 24:1976-87.
15. Yatsula B, Lin S, Read AJ. Identification of binding sites of EVI1 in mammalian cells. J Biol Chem 2005, 280:30 712-22.
16. Kreider BL, Orkin SH, Ihle JN. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc Natl Acad Sci USA 1993, 90:6454-8.
17. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001, 97:2815-22.
18. Palmer S, Brouillet JP, Kilbey A. Evi-1 transforming and repressor activities are mediated by CtBP co-repressor proteins. J Biol Chem 2001, 276:25 834-40.
19. Vinatzer U, Taplick J, Seiser C, Fonatsch C, Wieser R. The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. Br J Haematol 2001, 114:566-73.
20. Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. J Biol Chem 2001, 276:44 936-43.
21. Spensberger D, Delwel R. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett 2008, 582:2761-7.
22. Cattaneo F, Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem 2008, 105:344-52.
23. Kurokawa M, Mitani K, Irie K. The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3. Nature 1998, 394:92-6.
24. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1. Leukemia 1999, 13:348-57.
25. Alliston T, Ko TC, Cao Y. Repression of BMP and activin-inducible transcription by Evi-1. J Biol Chem 2005, 280:24227-37.
26. Kurokawa M, Mitani K, Yamagata T. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000, 19:2958-68.
27. Buonamici S, Li D, Mikhail FM. EVI1 abrogates interferon-α response by selectively blocking PML induction. J Biol Chem 2005, 280:428-36.
28. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFβ- and taxol-mediated cell death via PI3K/AKT. Oncogene 2006, 25:3565-75.
29. Tanaka T, Nishida J, Mitani K, Ogawa S, Yazaki Y, Hirai H. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J Biol Chem 1994, 269:24 020-6.
30. Sato T, Goyama S, Nitta E. Evi-1 promotes para-aortic splanchnopleural hematopoiesis through upregulation of GATA-2 and repression of TGF-β signaling. Cancer Sci 2008, 99:1407-13.
31. Hoyt PR, Bartholomew C, Davis AJ. The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 1997, 65:55-70.
32. Goyama S, Yamamoto G, Shimabe M. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008, 3:207-20.
33. Morishita K, Parganas E, Matsugi T, Ihle JN. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol 1992, 12:183-9.
34. Laricchia-Robbio L, Nucifora G. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis 2008, 40:141-7.
35. Buonamici S, Li D, Chi Y. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 2004, 114:713-19.
36. Laricchia-Robbio L, Fazzina R, Li D. Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells. Mol Cell Biol 2006, 26:7658-66.
37. Sitailo S, Sood R, Barton K, Nucifora G. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Leukemia 1999, 13:1639-45.
38. Shimizu S, Nagasawa T, Katoh O, Komatsu N, Yokota J, Morishita K. EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem Biophys Res Commun 2002, 292:609-16.
39. Metais JY, Dunbar CE. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol Ther 2008, 16:439-49.
40. Ott MG, Schmidt M, Schwarzwaelder K. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006, 12:401-9.
41. Calmels B, Ferguson C, Laukkanen MO. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 2005, 106:2530-3.
42. Kustikova O, Fehse B, Modlich U. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 2005, 308:1171-4.
43. Louz D, van den Broek M, Verbakel S. Erythroid defects and increased retrovirally-induced tumor formation in Evi1 transgenic mice. Leukemia 2000, 14:1876-84.
44. Cuenco GM, Ren R. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene 2004, 23:569-79.
45. Jin G, Yamazaki Y, Takuwa M. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 2007, 109:3998-4005.
46. Watanabe-Okochi N, Kitaura J, Ono R. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 2008, 111:4297-308.
47. Peeters P, Wlodarska I, Baens M. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Cancer Res 1997, 57:564-9.
48. Nucifora G, Begy CR, Kobayashi H. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA 1994, 91:4004-8.
49. Morishita K, Parganas E, William CL. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992, 89:3937-41.
50. Suzukawa K, Parganas E, Gajjar A. Identification of a breakpoint cluster region 3′ of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994, 84:2681-8.
51. Pintado T, Ferro MT, San Roman C, Mayayo M, Larana JG. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 1985, 55:535-41.
52. Valk PJ, Verhaak RG, Beijen MA. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-28.
53. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003, 101:837-45.
54. Lugthart S, van Drunen E, van Norden Y. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008, 111:4329-37.
55. Haas K, Kundi M, Sperr WR. Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML. EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer 2008, 47:288-98.
56. Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res 2006, 66:11 360-9.
57. Raza A, Buonamici S, Lisak L. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004, 28:791-803.